Loading
A phase 3 trial of Sacituzumab govitecan and Capecitabine in HR-positive / HER2-negative breast cancer, run by Gilead Sciences, active and no longer recruiting.
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy is a phase 3 interventional study registered as NCT05840211 by Gilead Sciences, with 654 participants enrolled, started 2023-05-08 and due to reach its primary completion in 2028-04. Interventions recorded: Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel and Capecitabine.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Capecitabine and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-low and HER2-ultralow metastatic breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), HR-positive / HER2-negative breast cancer and the tag pipeline.